Norton Rose Fulbright advises Rothschild as financial adviser to Charterhouse on £235 million recommended offer for Animalcare Group

Global law firm Norton Rose Fulbright is advising Rothschild & Co (Rothschild) as financial adviser to Charterhouse Capital Partners LLP and CCP Paw2 Bidco Limited, a wholly-owned indirect subsidiary of funds managed or advised by Charterhouse on its £235 million recommended cash offer for Animalcare Group plc (Animalcare).

Charterhouse is one of the longest established private equity firms operating in Europe, having built a strong reputation through over 80 years of active investments in private equity and over 35 years of buy-outs. Charterhouse typically invests in companies headquartered in Western Europe and works closely with incumbent management teams providing them with active support to drive growth. Charterhouse has approximately €7bn of funds under management and follows a selective, conviction-led approach to investing in high-quality mid-market companies headquartered in Europe. Charterhouse has 65 team members, including 17 partners and 35 investment professionals, all of whom are based in its London headquarters.

Headquartered in York (UK), Animalcare is an animal healthcare company focused on the development and commercialisation of products for companion animals, equine, and production animals. The company has approximately 165 animal health pharma brands across multiple markets and therapeutic areas, with its core focus on pain management, anaesthetics & analgesics, fluid therapy, gastric ulcer and non-antibiotic anti-infectives, and dental products. Animalcare has a long established presence in Europe, with a recent expansion into APAC through its acquisition of Randlab. Animal Care shares are traded on AIM (ANCR).

The London-based Norton Rose Fulbright team is being led by corporate partner Paul Whitelock supported by corporate associate Katherine MacPhail.